Zura Bio

ZURA

Market cap $124M

Overview Fund Activity

1.90 USD

-0.06

3.06%

At close Updated Sep 17, 4:00 PM EDT

1 day

-3.06%

5 days

-8.65%

1 month

9.2%

3 months

66.67%

6 months

39.71%

Year to date

-19.15%

1 year

-51.03%

5 years

-80.41%

10 years

-80.41%

About: Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Employees: 30

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

13% less funds holding

Funds holding: 75 [Q1] → 65 (-10) [Q2]

15.17% less ownership

Funds ownership: 66.87% [Q1] → 51.7% (-15.17%) [Q2]

16% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 19

33% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 30

37% less capital invested

Capital invested by funds: $59M [Q1] → $37.1M (-$21.9M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2

5% upside

Avg. target

$9.33

391% upside

High target

$16

742% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

HC Wainwright & Co. Mitchell S. Kapoor	$2	Neutral Maintained	19 Aug 2025
Oppenheimer Justin Kim	$16	Outperform Maintained	15 Aug 2025
Chardan Capital Daniil Gataulin	$10	Buy Maintained	15 Aug 2025

See Analyst Rankings

Financial journalist opinion

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor me.

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “The second quarter of 2025 marked continued progress across our clinical programs and organizational goals,” said Robert Li.

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported that on July 15, 2025, the Company granted inducement awards consisting of options to purchase up to 890,950 Class A Ordinary Shares (the “Options”) to seven newly hired employees, which includes an award of 672,000 Options granted to Eric Hyll.

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Announces Chief Financial Officer Transition

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transi.

Zura Bio Announces Chief Financial Officer Transition

Zura Bio to Present at the Jefferies Global Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present a corporate overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 3:10 PM ET in New York, NY. In addition, the Company will participate in one-on-one meeti.

Zura Bio to Present at the Jefferies Global Healthcare Conference

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa.

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. “The first quarter of 2025 reflected steady progress across our clinical and operational priorities,” said Robert Lisicki, Chief Executive Offi.

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates. “In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a le.

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL. A live webcast and a replay of the presentation.

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Zacks Investment Research

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

Zura Bio Limited (ZURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

See News Rankings

Charts implemented using Lightweight Charts™